Common use of Information and Reporting Clause in Contracts

Information and Reporting. Oragenics will keep Intrexon informed about Oragenics’ efforts to develop and Commercialize Oragenics Products, including reasonable and accurate summaries of Oragenics’ (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization of the Oragenics Products, including initiation or completion of a clinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, clinical or product safety event, receipt of regulatory approval or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.8 above, Oragenics shall also provide to Intrexon copies of all final preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Oragenics as soon as practical after they become available. Intrexon will keep Oragenics informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Oragenics Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 above, such disclosures by Oragenics and Intrexon will be coordinated by the JSC and made in connection with JSC meetings at least once every six (6) months while Oragenics Products are being developed or Commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

Information and Reporting. Oragenics AquaBounty will keep Intrexon informed about Oragenics’ AquaBounty’s efforts to develop and Commercialize Oragenics AquaBounty Products, including reasonable and accurate summaries of Oragenics’ AquaBounty’s (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization of the Oragenics AquaBounty Products, including initiation or completion of a clinical regulatory trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, clinical or product safety event, receipt of regulatory approval Regulatory Approval, or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.8 3.7 above, Oragenics AquaBounty shall also provide Intrexon access to Intrexon copies of all final preclinical protocols and reports, final clinical regulatory trial protocols and reports, and regulatory correspondence and filings generated by Oragenics AquaBounty as soon as practical after they become available. Intrexon will keep Oragenics AquaBounty informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Oragenics AquaBounty Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Aquaculture Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord accordance with Section 4.2 above, such disclosures by Oragenics AquaBounty and Intrexon will be coordinated by the JSC and made in connection with JSC meetings at least once every six (6) months while Oragenics AquaBounty Products are being developed or Commercialized anywhere in the world, and shall be reflected in the minutes of such meetings. Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Information and Reporting. Oragenics will keep Intrexon informed about Oragenics’ efforts to develop and Commercialize commercialize Oragenics Products, including reasonable and accurate summaries of Oragenics’ (and its Affiliates’ and, if applicable, (sub)licensees’) global Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization commercialization of the Oragenics Products, including initiation or completion of a clinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, clinical or product safety event, receipt of regulatory approval Regulatory Approval, or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.8 above, Oragenics shall also provide to Intrexon copies of all final preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Oragenics as soon as practical after they become available. Intrexon will keep Oragenics informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Oragenics Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Lantibiotics Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 aboveherein, such disclosures by Oragenics and Intrexon will be coordinated by the JSC and made in connection with the course of JSC meetings at least once every six (6) months while Oragenics Products are being developed or Commercialized commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

Information and Reporting. Oragenics Synthetic will keep Intrexon informed about Oragenics’ Synthetic’s efforts to develop and Commercialize Oragenics commercialize Synthetic Products, including reasonable and accurate summaries of Oragenics’ Synthetic’s (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization commercialization of the Oragenics Synthetic Products, including initiation or completion of a clinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, clinical or product safety event, receipt of regulatory approval Regulatory Approval, or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.8 above, Oragenics Synthetic shall also provide to Intrexon copies of all final preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Oragenics Synthetic as soon Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. as practical after they become available. Intrexon will keep Oragenics Synthetic informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Oragenics Synthetic Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Anti-Infectives Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 aboveherein, such disclosures by Oragenics Synthetic and Intrexon will be coordinated by the JSC and made in connection with the course of JSC meetings at least once every six (6) months while Oragenics Synthetic Products are being developed or Commercialized commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

Information and Reporting. Oragenics Soligenix will keep Intrexon informed about Oragenics’ Soligenix’s efforts to develop and Commercialize Oragenics Soligenix Products, including reasonable and accurate summaries of Oragenics’ Soligenix’s (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization of the Oragenics Soligenix Products, including initiation or completion of a clinical trialRegulatory Trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, clinical or product Soligenix Product adverse safety eventevents, receipt of regulatory approval Regulatory Approval, or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.8 3.7 above, Oragenics Soligenix shall also provide to Intrexon copies of all final preclinical protocols and reports, final clinical Regulatory Trial protocols and reports, and regulatory correspondence and filings generated by Oragenics Soligenix as soon as practical after they become available. Intrexon will keep Oragenics Soligenix informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Oragenics Soligenix Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Melioidosis Program with respect to the Intrexon Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 above, such disclosures by Oragenics Soligenix and Intrexon will be coordinated by the JSC and made in connection with JSC meetings at least once every six (6) months while Oragenics Soligenix Products are being developed or Commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

Information and Reporting. Oragenics will keep Intrexon informed about Oragenics’ efforts to develop and Commercialize Oragenics Products, including reasonable and accurate summaries of Oragenics’ (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization of the Oragenics Products, including initiation or completion of a clinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, clinical or product safety event, receipt of regulatory approval or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.8 above, Oragenics shall also provide to Intrexon copies of all final preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Oragenics as soon as practical after they become available. Intrexon will keep Oragenics informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Oragenics Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Probiotics Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 above, such disclosures by Oragenics and Intrexon will be coordinated by the JSC and made in connection with JSC meetings at least once every six (6) months while Oragenics Products are being developed or Commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

Information and Reporting. Oragenics will keep Intrexon EGI informed about Oragenics’ efforts to develop and Commercialize commercialize Oragenics Products, including reasonable and accurate summaries of Oragenics’ (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization commercialization of the Oragenics Products, including initiation or completion of a clinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, clinical or product safety event, receipt of regulatory approval Regulatory Approval, or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.8 above, Oragenics shall also provide to Intrexon EGI copies of all final preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Oragenics as soon as practical after they become available. Intrexon EGI will keep Oragenics informed about IntrexonEGI’s efforts (a) to establish manufacturing capabilities and facilities for Oragenics Products (and Intrexon EGI Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Lantibiotics Program with respect to the Intrexon EGI Channel Technology and Intrexon EGI Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 aboveherein, such disclosures by Oragenics and Intrexon EGI will be coordinated by the JSC and made in connection with the course of JSC meetings at least once every six (6) months while Oragenics Products are being developed or Commercialized commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

Information and Reporting. Oragenics will keep Intrexon informed about Oragenics’ efforts to develop and Commercialize commercialize Oragenics Products, including reasonable and accurate summaries of Oragenics’ (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization commercialization of the Oragenics Products, including initiation or completion of a clinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, clinical or product safety event, receipt of regulatory approval Regulatory Approval, or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.8 above, Oragenics shall also provide to Intrexon copies of all final preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Oragenics as soon as practical after they become available. Intrexon will keep Oragenics informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Oragenics Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Lantibiotics Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 aboveherein, such disclosures by Oragenics and Intrexon will be coordinated by the JSC and made in connection with the course of JSC meetings at least once every six (6) months while Oragenics Products are being developed or Commercialized commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

Information and Reporting. Oragenics Fibrocell will keep Intrexon informed about Oragenics’ Fibrocell’s efforts to develop and Commercialize Oragenics Collaboration Products, including reasonable and accurate summaries of Oragenics’ Fibrocell’s (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization of the Oragenics Collaboration Products, including initiation or completion of a clinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, clinical or product safety event, receipt of regulatory approval approval, or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.8 above, Oragenics Fibrocell shall also provide to Intrexon copies of all final preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Oragenics Fibrocell as soon as practical after they become available. Intrexon will keep Oragenics Fibrocell informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Oragenics Collaboration Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord accordance with Section 4.2 above, such disclosures by Oragenics Fibrocell and Intrexon will be coordinated by the JSC and made in connection with the course of JSC meetings at least once every six (6) months while Oragenics Collaboration Products are being developed or Commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

Information and Reporting. Oragenics Soligenix will keep Intrexon informed about Oragenics’ Soligenix’s efforts to develop and Commercialize Oragenics Soligenix Products, including reasonable and accurate summaries of Oragenics’ Soligenix’s (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization of the Oragenics Soligenix Products, including initiation or completion of a clinical trialRegulatory Trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, clinical or product Soligenix Product adverse safety eventevents, receipt of regulatory approval Regulatory Approval, or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.8 3.7 above, Oragenics Soligenix shall also provide to Intrexon copies of all final preclinical protocols and reports, final clinical Regulatory Trial protocols and reports, and regulatory correspondence and filings generated by Oragenics Soligenix as soon as practical after they become available. Intrexon will keep Oragenics Soligenix informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Oragenics Soligenix Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Melioidosis Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 above, such disclosures by Oragenics Soligenix and Intrexon will be coordinated by the JSC and made in connection with JSC meetings at least once every six (6) months while Oragenics Soligenix Products are being developed or Commercialized anywhere in the world, and shall be reflected in the minutes of such meetings. Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Information and Reporting. Oragenics Synthetic will keep Intrexon informed about Oragenics’ Synthetic’s efforts to develop and Commercialize Oragenics Collaboration Products, including reasonable and accurate summaries of Oragenics’ Synthetic’s (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated)) for Collaboration Products, including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization of the Oragenics Collaboration Products, including initiation or completion of a clinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, clinical or product safety event, receipt of regulatory approval approval, or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.8 above, Oragenics Synthetic shall also provide to Intrexon copies of all final preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Oragenics Synthetic as soon as practical after they become available. Intrexon will keep Oragenics Synthetic informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Oragenics Collaboration Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 aboveherein, such disclosures by Oragenics Synthetic and Intrexon will be coordinated by the JSC and made in connection with JSC meetings at least once every six (6) months while Oragenics Collaboration Products are being developed or Commercialized anywhere in the world, and shall be reflected in the minutes of such meetings. Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

Information and Reporting. Oragenics Synthetic will keep Intrexon informed about Oragenics’ Synthetic’s efforts to develop and Commercialize Oragenics commercialize Synthetic Products, including reasonable and accurate summaries of Oragenics’ Synthetic’s (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization commercialization of the Oragenics Synthetic Products, including initiation or completion of a clinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, clinical or product safety event, receipt of regulatory approval Regulatory Approval, or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.8 above, Oragenics Synthetic shall also provide to Intrexon copies of all final preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Oragenics Synthetic as soon as practical after they become available. Intrexon will keep Oragenics Synthetic informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Oragenics Synthetic Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Anti-Infectives Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 aboveherein, such disclosures by Oragenics Synthetic and Intrexon will be coordinated by the JSC and made in connection with the course of JSC meetings at least once every six (6) months while Oragenics Synthetic Products are being developed or Commercialized commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.

Information and Reporting. Oragenics BioLife will keep Intrexon informed about Oragenics’ BioLife’s efforts to develop and Commercialize Oragenics and, upon successful execution by BioLife of its option under Section 5.1, commercialize BioLife Products, including reasonable and accurate summaries of Oragenics’ Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. BioLife’s (and its Affiliates’ and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of any material deviations, and significant developments in the development and/or Commercialization commercialization of the Oragenics BioLife Products, including initiation or completion of a clinical trial, submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, clinical or product safety event, receipt of regulatory approval Regulatory Approval, or commercial launch, and manufacturing costs and pricing information. As set forth in Section 3.8 above, Oragenics BioLife shall also provide to Intrexon copies of all final preclinical protocols and reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Oragenics BioLife as soon as practical after they become available. Intrexon will keep Oragenics BioLife informed about Intrexon’s efforts (a) to establish manufacturing capabilities and facilities for Oragenics BioLife Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the SMA Therapeutics Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.2 aboveherein, such disclosures by Oragenics BioLife and Intrexon will be coordinated by the JSC and made in connection with the course of JSC meetings at least once every six (6) months while Oragenics BioLife Products are being developed or Commercialized commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.